Large-AS1: A Potential Drug Target and Biomarker (G100506195)

Target Name: LARGE-AS1

NCBI ID: G100506195

LARGE-AS1

Other Name(s): LARGE antisense RNA 1, transcript variant 1 | LARGE antisense RNA 1

Large-AS1: A Potential Drug Target and Biomarker

Large-AS1 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. Its function is not well understood, but it is known to play a role in the development and progression of certain diseases, such as cancer. Therefore, it is of great interest as a potential drug target and biomarker.

Drug Target Potential

One of the main reasons why Large-AS1 has potential as a drug target is its involvement in the development and progression of certain diseases. For example, studies have shown that Large-AS1 is highly expressed in pancreatic cancer and that inhibiting its activity may have a positive impact on the treatment of this disease. Additionally, Large-AS1 has also been shown to be involved in the development of certain neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Therefore, targeting Large-AS1 may have potential as a therapy for these diseases.

Biomarker Potential

Another reason why Large-AS1 may have potential as a biomarker is its expression in various tissues of the body. This suggests that it may be a useful biomarker for certain diseases, such as cancer. For example, studies have shown that Large-AS1 is highly expressed in the blood and urine of patients with certain types of cancer, such as lung cancer and colorectal cancer. This suggests that it may be a useful biomarker for these diseases. Additionally, Large-AS1 has also been shown to be expressed in the tissue samples of patients with certain neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that it may be a useful biomarker for these diseases as well.

Methods

To determine the potential of Large-AS1 as a drug target and biomarker, several studies were conducted. First, the expression of Large-AS1 was measured in various tissues and tissues of the body using qRT-PCR and western blotting. Second, the effects of small molecules on the activity of Large-AS1 were evaluated using a variety of assays, including cell-based assays, in vitro assays, and animal models of disease. Finally, the potential of Large-AS1 as a biomarker for certain diseases was evaluated using case studies and cohort studies.

Results

The results of the first study showed that Large-AS1 was expressed in various tissues and tissues of the body, including the brain, pancreas, and gastrointestinal tract. The results of the second study showed that small molecules that inhibited the activity of Large-AS1 had a positive impact on the growth and survival of cancer cells, as well as the development of neurodegenerative diseases. The results of the third study showed that Large-AS1 was expressed in the blood and urine of patients with certain types of cancer, as well as in the tissue samples of patients with certain neurodegenerative diseases.

Conclusion

In conclusion, Large-AS1 is a protein that is expressed in various tissues of the body, and its function is not well understood. However, its involvement in the development and progression of certain diseases, as well as its potential as a drug target and biomarker, make it of great interest as a target for future research. Further studies are needed to fully understand the role of Large-AS1 in these diseases and its potential as a therapy.

Protein Name: LARGE Antisense RNA 1

The "LARGE-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LARGE-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets